Evidence from numerous clinical studies shows the ability of GLP-1R agonists to reduce cancer risk in many people with T2D or obesity, but most studies have not yet investigated how these therapies affect cancer risk in people without metabolic diseases, nor whether GLP-1R therapies will reduce cancer-specific mortality. Here, GLP1R is linked to type 2 diabetes mellitus.